Crossmark

Efficacy, safety, and exploratory biomarker analysis of rechallenge with immune checkpoint inhibitors combined with anlotinib in previously treated advanced non-small cell lung cancer

Crossref DOI link: https://doi.org/10.1186/s12890-025-04093-y

Published Online: 2026-01-26

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Liu, Li

Yang, Haiyan

Xiong, Yi

Zhou, Chunhua

Jiang, Wenjuan

Pu, Xingxiang

Heng, Jianfu
Funding

Funding for this research was provided by:

the science and technology innovation Program of Hunan Province (2021SK51101)

High-Level Talent Support Program of Hunan Cancer Hospital (20250806-1003)
License Information

Text and Data Mining valid from 2026-01-26

Accepted Manuscript valid from 2026-01-26
More Information

Article History

Received: 18 September 2025

Accepted: 26 December 2025

First Online: 26 January 2026

Declarations

:

: The study was conducted in accordance with the Declaration of Helsinki and was approved by the Ethics Committee of Hunan Cancer Hospital (Approval No: SBQLL-2021-092).

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below